PMID- 9715813
OWN - NLM
STAT- MEDLINE
DCOM- 19981105
LR  - 20190712
IS  - 0091-3057 (Print)
IS  - 0091-3057 (Linking)
VI  - 61
IP  - 1
DP  - 1998 Sep
TI  - Localizing haloperidol effects on sensorimotor gating in a predictive model of 
      antipsychotic potency.
PG  - 113-9
AB  - The degree to which a startle response to a loud noise is inhibited by a weak 
      prestimulus is an operational measure of sensorimotor gating. Prepulse inhibition 
      (PPI) can be measured across species and is reduced in schizophrenia patients and 
      dopamine (DA)-activated rats. The ability of DA antagonists to restore PPI in 
      apomorphine (APO)-treated rats correlates highly with their clinical 
      antipsychotic potency. We compared the ability of systemic- vs. intracerebrally 
      (i.c.)-administered haloperidol (HAL) to restore PPI in APO-treated rats. 
      Consistent with previous studies, systemic administration of HAL completely 
      restored PPI in rats treated with APO (0.5 mg/kg s.c.), with an ED50 of 
      approximately 0.02 mg/kg. In an otherwise identical paradigm, HAL failed to fully 
      restore PPI after infusion into either the nucleus accumbens (NACcore or 
      NACshell), NACcore + caudate nucleus (CN), ventral subiculum (VS), medial 
      prefrontal cortex (MPFC), or ventral tegmentum (VTA). A subtotal, but 
      statistically significant restoration of PPI was achieved after HAL infusion into 
      all regions, except the NACshell. Statistically significant effects of i.c. HAL 
      tended to be observed at doses that were only approximately 5-10-fold lower than 
      those at which significant effects were observed after systemic administration. 
      The results suggest that systemically administered HAL may restore PPI in 
      APO-treated rats through its action distributed throughout multiple levels of 
      PPI-regulatory circuitry.
FAU - Hart, S
AU  - Hart S
AD  - Department of Psychiatry, UCSD School of Medicine, La Jolla, CA 92093-0804, USA.
FAU - Zreik, M
AU  - Zreik M
FAU - Carper, R
AU  - Carper R
FAU - Swerdlow, N R
AU  - Swerdlow NR
LA  - eng
GR  - MH 01436/MH/NIMH NIH HHS/United States
GR  - MH 42228/MH/NIMH NIH HHS/United States
GR  - MH 48381/MH/NIMH NIH HHS/United States
GR  - etc.
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Pharmacol Biochem Behav
JT  - Pharmacology, biochemistry, and behavior
JID - 0367050
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Dopamine Agonists)
RN  - J6292F8L3D (Haloperidol)
RN  - N21FAR7B4S (Apomorphine)
SB  - IM
MH  - Animals
MH  - Antipsychotic Agents/*pharmacology
MH  - Apomorphine/pharmacology
MH  - Brain/anatomy & histology/*drug effects
MH  - Dopamine Agonists/pharmacology
MH  - Haloperidol/*pharmacology
MH  - Male
MH  - Models, Psychological
MH  - Predictive Value of Tests
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Reflex, Startle/*drug effects
EDAT- 1998/08/26 00:00
MHDA- 1998/08/26 00:01
CRDT- 1998/08/26 00:00
PHST- 1998/08/26 00:00 [pubmed]
PHST- 1998/08/26 00:01 [medline]
PHST- 1998/08/26 00:00 [entrez]
AID - S0091-3057(98)00079-3 [pii]
AID - 10.1016/s0091-3057(98)00079-3 [doi]
PST - ppublish
SO  - Pharmacol Biochem Behav. 1998 Sep;61(1):113-9. doi: 
      10.1016/s0091-3057(98)00079-3.